Proposed 1st WHO International Standards for Cancer Genomes
NIBSC is currently preparing the proposed WHO 1
st International Standards for Cancer Genomes; three genomic DNAs of two cancer and one wildtype genomes.
These materials are intended as both calibrants in the quantification of (predicted) clinically-relevant variants PIK3CA p.E454K, TP53 p.R306*, NRAS p.G12C, PTEN p.K267fs*9, and MAP2K1/MEK1 p.D67N, and as reference materials to validate assay performance with multiple other genome-wide variants in these pan-cancer materials.
Help us assess the proposed standards
We’re looking for participants to join an international study evaluating the performance of the materials across a range of methods.
Participants should routinely perform quantitative testing for at least one of the clinically-relevant variants (PIK3CA p.E454K, TP53 p.R306*, NRAS p.G12C, PTEN p.K267fs*9, and MAP2K1/MEK1 p.D67N), for example by digital PCR or next-generation sequencing, and be able to evaluate the materials in October-November 2018.
Your results will support the assignment of consensus values for the (predicted) clinically-relevant variants, and provide a large dataset for additional other variants.
Contribution to the assessment of these materials would be acknowledged in the WHO report for these standards and in any resulting publications.
If you’d like to participate in this important standardisation initiative, please contact Pia.Sanzone@nibsc.org.
Recruitment closing date: 21 September 2018.